schemaVersion:

1-K: Filer Information

Issuer CIK
0001772028 
Issuer CCC
XXXXXXXX 
Is filer a shell company? Radio button not checked Yes Radio button checked No
Is the electronic copy of an official filing submitted in paper format? Checkbox not checked
File Number
 
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? Radio button not checked Yes Radio button checked No
Successor File Number
 

Submission Contact Information

Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
Would you like a Return Copy? Checkbox not checked
Period
12-31-2019 
Name
 
Phone
 
E-Mail Address
 
Notify via Filing Website only? Checkbox not checked

1-K: Tab 1 Notification

This Form 1-K is to provide an Radio button checked Annual Report Radio button not checked Special Financial Report for the fiscal year
Fiscal Year End

12-31-2019 

Exact name of issuer as specified in the issuer's charter

Scopus BioPharma Inc. 

CIK

0001772028 

Jurisdiction of Incorporation / Organization

DELAWARE  

I.R.S. Employer Identification Number

82-1248020 

Address of Principal Executive Offices

Address 1

420 LEXINGTON AVENUE, SUITE 300 

Address 2

 

City

NEW YORK 

State/Country

NEW YORK  

Mailing Zip/ Postal Code

10170 

Phone

212-479-2513 

Title of each class of securities issued pursuant to Regulation A

None 

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Checkbox not checkedThe following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement

024-11137 

Date of qualification of the offering statement

02-04-2020 

Date of commencement of the offering

02-10-2020 

Amount of securities qualified to be sold in the offering

200000 

Amount of securities sold in the offering

0 

Price per security

$ 5.0000 

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 0.00 

The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders

$ 0.00 

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider Underwriters - Fees
$  
Sales Commissions - Name of Service Provider Sales Commissions - Fee
$  
Finders' Fees - Name of Service Provider Finders' Fees - Fees
$  
Accounting or Audit - Name of Service Provider Accounting or Audit - Fees
$  
Legal - Name of Service Provider Legal - Fees
$  
Promoters - Name of Service Provider Promoters - Fees
$  
Blue Sky Compliance - Name of Service Provider Blue Sky Compliance - Fees
$  
CRD Number of any broker or dealer listed

 

Net proceeds to the issuer

$  

Clarification of responses (if necessary)

As of the date hereof, no Series A Units under offering statement no. 024-11137, which was qualified on February 4, 2020 and supplemented on February 10, have been sold. The offering thereunder has not yet commenced and has not been terminated.